Merck & Co., Inc. vs Solaredge Technologies Inc — how do they compare? Merck & Co., Inc. trades at $146.21 (market cap $351.28B), while Solaredge Technologies Inc trades at $31.92 (market cap $2.00B). The key difference: Merck & Co., Inc. is far larger — about 175.6× Solaredge Technologies Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Solaredge Technologies Inc for 34 Days on average.
| MRK | SEDG | |
|---|---|---|
Market Cap | $351.28B | $2.00B |
Volume | 7,969,665 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $156.43 | $78.51 |
52-Week Low | $82.49 | $28.47 |
Typical Hold Time | 98 Days | 34 Days |
Enterprise Value | $398.04B | $1.86B |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
SolarEdge Technologies (SEDG) trades at $31.81, down 4.07% on the day, reflecting ongoing volatility amid a bearish technical signal and mixed earnings. The stock faces fundamental headwinds with a net loss of $405.45 million in 2025 and negative profit margins, though revenue grew to $1.18 billion. Recent news highlights legal investigations and AI data center initiatives, while analyst sentiment remains cautious with a $37.75 consensus target.
The outlook for SEDG is challenged by persistent losses and competitive pressures, but potential upside exists if AI-driven growth targets materialize. Key risks include execution on new initiatives, solar industry financing costs, and legal overhangs. Investors should weigh the high-risk profile against long-term transformation efforts under current market conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →